US FDA approves Daiichi Sankyo’s acute myeloid leukaemia treatment
The US FDA has granted approval for Daiichi Sankyo’s Vanflyta to treat adults with FLT3-ITD positive acute myeloid leukaemia (AML).
The US FDA has granted approval for Daiichi Sankyo’s Vanflyta to treat adults with FLT3-ITD positive acute myeloid leukaemia (AML).
What's Your Reaction?
